Effects on suicidal risk: comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder
| Autor: | Maurizio Pompili, Martina Mastrangelo, Benedetta Montalbani, Benedetta Imbastaro, Alberto Forte, Gabriele Pasquale De Luca, Ross J. Baldessarini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Suicide Prevention
medicine.medical_specialty bipolar disorder drugs for psychosis schizophrenia suicide Suicidal risk Suicide Attempted Suicidal Ideation 03 medical and health sciences 0302 clinical medicine Medicine Humans Pharmacology (medical) Bipolar disorder Psychiatry Clozapine Pharmacology business.industry medicine.disease 030227 psychiatry Psychiatry and Mental health Schizophrenia business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Popis: | Background: Clozapine is the only treatment with regulatory-recognition of lowering suicidal risk, at least in schizophrenia patients. It remains uncertain whether such effects extend to other drugs for psychosis. Methods: We searched for reports on rates of suicidal behavior during treatment with clozapine and other modern drugs for psychosis (aripiprazole, olanzapine, risperidone, quetiapine, and ziprasidone) versus comparison or control treatments and analyzed the contrasts by random-effect meta-analysis to obtain pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: We identified 35 paired comparisons of modern drugs for psychosis versus comparison or control treatments in 18 reports. There was moderate overall superiority of all agents tested over alternatives (OR = 0.522, p = 0.004). With clozapine, this effect was large (OR = 0.229, p Conclusions: An ability of clozapine to reduce risk of suicides and attempts in schizophrenia patients appears to be a unique effect not shared with other modern medicines indicated for schizophrenia or bipolar disorder. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|